Ono Pharmaceutical (OTCMKTS:OPHLF) Sees Unusually-High Trading Volume – Still a Buy?

Ono Pharmaceutical Co. (OTCMKTS:OPHLF) saw unusually-strong trading volume on Tuesday . Approximately 1,086 shares traded hands during mid-day trading, an increase of 199% from the previous session’s volume of 363 shares.The stock last traded at $15.63 and had previously closed at $14.90.

Analysts Set New Price Targets

Separately, Zacks Research raised shares of Ono Pharmaceutical to a “hold” rating in a research note on Friday, April 17th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the company presently has a consensus rating of “Hold”.

Ono Pharmaceutical Trading Up 4.9%

The company has a 50 day moving average of $14.38 and a 200 day moving average of $14.65. The firm has a market cap of $7.34 billion, a P/E ratio of 15.79 and a beta of 0.34. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.56 and a current ratio of 3.02.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.